Friday 12 July 2013
Responding to today’s launch of the report Realising the potential of stratified medicine from the Academy of Medical Sciences, Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, London, said:
“I’m very excited about the potential of stratified medicine – and beyond that, fully personalised medicine – for treating cancer. Indeed some targeted drugs, such as the example of vemurafenib highlighted in today’s report, are already making a real difference to cancer patients in the UK.vem
“It was never going to be straightforward to turn the promise of personalised medicine into reality, partly because the more we learn about the genetics of tumours, the more intricate they turn out to be. But we are making real and measurable progress, and as our knowledge of cancer genetics accelerates and with enhanced collaboration between academia and industry, I would expect to see more targeted drugs like vemurafenib, trastuzumab and imatinib in the near future.”
Related stories
How the ICR is helping to realise the potential of stratified medicine, from the ICR Research Blog